Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Gingivitis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 4
- 主要终点
- Gingival Index (GI) at Day 7
研究概览
简要总结
Gingivitis is a reversible inflammation of the gums caused by the accumulation of dental plaque. Without appropriate intervention-such as proper oral hygiene and plaque removal-gingivitis can progress to periodontitis, leading to clinical attachment loss, alveolar bone resorption, and ultimately tooth loss. Gingivitis can be managed with regular and proper tooth brushing and the use of interdental brushes. In cases of more extensive inflammation affecting multiple or all teeth, dental treatment may be required, including scaling, air polishing, or both. Depending on the dentist's assessment, inflamed gums may also be treated with antibiotic therapy.
As an adjunctive therapy to manage inflamed gums and maintain proper oral hygiene, the use of mouth rinses or oral solutions containing chlorhexidine, hyaluronic acid, chitosan, or active oxygen (peroxide) is recommended. These agents have antimicrobial properties, help reduce plaque accumulation, and support tissue healing. Mouth rinses containing hydrogen peroxide have been used for over a century as an adjunct to mechanical plaque removal and for the prevention or management of oral infections. Despite long-term use, clinical studies on hydrogen peroxide-based mouth rinses are limited and vary in design, which makes comparison of results difficult.
One of the objectives of the proposed post-marketing clinical study is to generate data on the safety and effectiveness of hydrogen peroxide mouth rinses as adjunctive therapy in the treatment of gingivitis. The study will evaluate two concentrations of hydrogen peroxide mouth rinses: a 1.5% solution (Oroxid® sensitive) and a 3% solution (Oroxid® forte).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Systemically healthy participants aged 18 years or older.
- •Presence of at least 20 natural teeth.
- •Probing pocket depth less than or equal to 3 mm.
- •Presence of bleeding on probing in more than 10% of sites.
- •Mean Gingival Index (Silness & Löe) of at least
- •Ability and willingness to follow oral hygiene instructions after the intervention.
- •Signed informed consent form after being informed about the study.
排除标准
- •Periodontal treatment within the last three months.
- •Diagnosis of periodontitis.
- •Use of mouth rinses or oral gels within the last month.
- •Use of antibiotic therapy within the last three months.
- •Known allergy or hypersensitivity to any components of the investigational products.
- •Ongoing treatment with antihypertensive, antilipemic, antiarrhythmic, or other cardiovascular medications.
- •Presence of systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic kidney disease, tuberculosis, or autoimmune disorders (e.g., lupus, scleroderma, Crohn's disease).
- •Use of immunosuppressive medications.
- •Ongoing orthodontic treatment, fixed orthodontic appliance, or removable denture.
- •Pregnant or breastfeeding women.
结局指标
主要结局
Gingival Index (GI) at Day 7
时间窗: Baseline and Day 7
Mean change in Gingival Index (Silness and Löe) scores from baseline to day 7, comparing the two active treatment groups (OROXID® forte and OROXID® sensitive) with the control group. The Gingival Index (GI) evaluates the severity of gingival inflammation on a scale of 0 to 3, based on redness, swelling, and bleeding on probing.
Plaque Index (PI) at Day 7
时间窗: Baseline and Day 7
Differences in Plaque Index (PI) scores between the active and control groups will be evaluated using the Silness and Löe Plaque Index. This index assesses the thickness of dental plaque along the gingival margin based on the following scoring criteria: Score 0 = No plaque score; 1 = Mild plaque along the gingival margin; Score 2 =Moderate layer of plaque along gingival margin, interdental spaces free; Score 3 = Abundant plaque along the gingival margin, interdental spaces filled with plaque. Higher scores indicate poorer oral hygiene and greater plaque accumulation.
Bleeding on Probing (BOP) at Day 7
时间窗: Baseline and Day 7
Difference in the presence of bleeding on probing (BOP) between the two active treatment groups and the control group after 7 days of treatment. BOP evaluates gingival inflammation by recording the presence/absence of bleeding within 30 seconds after gentle periodontal probing, serving as a key diagnostic indicator of active periodontal disease.
次要结局
- Plaque Index (PI) at Day 14 and 28(Baseline, Day 14, and Day 28)
- Gingival Index (GI) at Day 14 and 28(Baseline, Day 14, and Day 28)
- Plaque Index (PI) at Day 14 and 28(Baseline, Day 14, and Day 28)
- Bleeding on Probing (BOP) at Day 14 and 28(Baseline, Day 14, and Day 28)
- Rate of infection(Baseline to Day 28)
- Adverse events(Baseline to Day 28)
